Shinichi Ichikawa
Niigata University of Pharmacy and Applied Life Sciences
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Shinichi Ichikawa.
Biochemistry Research International | 2012
Michiyo Nagano-Ito; Shinichi Ichikawa
Translationally controlled tumor protein (TCTP) is a highly conserved protein found in eukaryotes, across animal and plant kingdoms and even in yeast. Mammalian TCTP is ubiquitously expressed in various tissues and cell types. TCTP is a multifunctional protein which plays important roles in a number of cell physiological events, such as immune responses, cell proliferation, tumorigenicity, and cell death, including apoptosis. Recent identification of TCTP as an antiapoptotic protein has attracted interest of many researchers in the field. The mechanism of antiapoptotic activity, however, has not been solved completely, and TCTP might inhibit other types of cell death. Cell death (including apoptosis) is closely linked to proliferation and tumorigenesis. In this context, we review recent findings regarding the role of TCTP in cell death, proliferation, and tumorigenesis and discuss the mechanisms.
FEBS Letters | 2009
Michiyo Nagano-Ito; Aoi Banba; Shinichi Ichikawa
We used retroviral‐mediated expression cloning to identify cDNAs that inhibit cell death induced by oxidative stress. To isolate the genes, we introduced a murine embryonic retroviral cDNA library into NIH/3T3 cells, and selected for cells resistant to hydrogen peroxide. The surviving cells were cloned, and the integrated cDNAs were rescued by polymerase chain reaction. Several of the isolated cDNAs are known to be involved in modulating the redox state of cells. Other cDNAs encode proteins known to suppress apoptosis caused by reasons other than oxidative stress. These included polyadenylate‐binding protein, cytosolic 1 (Pabpc1) and translationally controlled tumor protein (TCTP).
Biochemical and Biophysical Research Communications | 2013
Satomi Niino; Yutaka Nakamura; Yoshio Hirabayashi; Michiyo Nagano-Ito; Shinichi Ichikawa
HA14-1 is a Bcl-2 inhibitor that is widely used for studies of apoptosis. In the course of searching for a ceramide glucosyltransferase inhibitor that catalyzes the first glycosylation step of glycosphingolipid synthesis, we unexpectedly found that HA-14-1 also has the ability to inhibit ceramide glucosyltransferase. The IC50 value of HA14-1 against ceramide glucosyltransferase is 4.5μM, which is lower than that reported for Bcl-2 in vitro. Kinetic analyses revealed that HA14-1 is a competitive and mixed-type inhibitor with respect to C6-NBD-ceramide and UDP-glucose, respectively.
Journal of Biochemistry | 2011
Junya Aida; Syouta Higuchi; Yoshie Hasegawa; Michiyo Nagano-Ito; Yoshio Hirabayashi; Aoi Banba; Takamitsu Shimizu; Asako Kikuchi; Mayuko Saga; Shinichi Ichikawa
The phorbol ester tetradecanoylphorbol acetate (TPA) induces promyelocytic leukaemia cells to differentiate to macrophage-like cells in vitro. During the course of this differentiation, the cells adhere to the bottom of the culture dish, a process that requires an increase in cell surface glycosphingolipids (GSLs). We examined the cellular content of glucosylceramide (GlcCer), the simplest of the GSLs, in a TPA-treated leukaemia cell line, U937. Following TPA treatment, we observed a 3.5-fold increase in GlcCer levels that was caused by enhanced activity of ceramide glucosyltransferase (GlcT-1), which catalyses ceramide glycosylation. Furthermore, in TPA-treated cell GlcT-1 amounts were increased at both the mRNA and protein levels. We also found decreased activity of lactosylceramide synthase in TPA-treated cells, which could also contribute to the increase in cellular GlcCer content.
Archive | 2006
Ichiro Miyoshi; Tadashi Okamura; Noriyuki Kasai; Tetsuyuki Kitmoto; Shinichi Ichikawa; Soh Osuka; Yoshio Hirabayashi
Genetically modified mice, created using transgenic technologies and gene targeting, are essential tools for clinical and fundamental research. In sphinoglipid research this became possible when the genes encoding enzymes in the sphingolipid metabolism pathway were identified and cloned. Using these mouse models, we can study the functions of sphingolipids in vivo. However, some of these knockout (KO) strains die in early developmental stages. This indicates that the enzymes and their products, sphingolipids, play a vital role during development. Conditional targeting, using the Cre-loxP system, avoids fetal lethality via a tissue-specific disruption of an allele. Alternatively, introducing tissue-specific transgenes encoding an enzyme with similar activity to that of the disrupted gene prevents embryonic lethality in KO mice. We established gene-modified mice deficient in ceramide glucosyltransferase or serine palmitoyltransferase to gain new insights into the roles of sphingolipids in vivo. These are the enzymes that take the first committed steps in sphingolipid synthesis, which includes the synthesis of ceramide, glycosphingolipid, and sphingomyelin. We found that sphingolipids are essential not only for early embryo development, but also for the formation and maintenance of certain organs.
Biochemical and Biophysical Research Communications | 2017
Hirotaka Tsurumaki; Hikaru Katano; Kousuke Sato; Ryou Imai; Satomi Niino; Yoshio Hirabayashi; Shinichi Ichikawa
WP1066 is a well-known inhibitor of the JAK/STAT3 signaling pathway. By a screen of known small molecule inhibitors of various enzymes and protein factors, we identified WP1066 as a ceramide glucosyltransferase inhibitor. Ceramide glucosyltransferase catalyzes the first glycosylation step during glycosphingolipid synthesis. We found that WP1066 inhibited the activity of ceramide glucosyltransferase with an IC50 of 7.2xa0μM, and that its action was independent of JAK/STAT3 pathway blockade. Moreover, the modes of inhibition of ceramide glucosyltransferase were uncompetitive with respect to both C6-NBD-cermide and UDP-glucose.
Evidence-based Complementary and Alternative Medicine | 2016
Tomohiro Takahashi; Wataru Sugawara; Yuya Takiguchi; Kento Takizawa; Ami Nakabayashi; Mitsuo Nakamura; Michiyo Nagano-Ito; Shinichi Ichikawa
Fatty liver disease is a condition in which abnormally large numbers of lipid droplets accumulate in liver cells. Fatty liver disease induces inflammation under conditions of oxidative stress and may result in cancer. To identify plants that protect against fatty liver disease, we examined the inhibitory effects of plant extracts on lipid droplet formation in mouse hepatoma cells. A screen of 98 water extracts of plants revealed 4 extracts with inhibitory effects. One of these extracts, Rubus suavissimus S. Lee (Tien-cha or Chinese sweet tea) leaf extract, which showed strong inhibitory effects, was tested in a mouse fatty liver model. In these mouse experiments, intake of the plant extract significantly protected mice against fatty liver disease without affecting body weight gain. Our results suggest that RSE directly affects liver cells and protects them from fatty liver disease.
Gene | 2007
Michiyo Nagano-Ito; Sae Yoshikawa; Mika Tamura; Mihoko Tsurumaki; Shinichi Ichikawa
The Japanese Biochemical Society/The Molecular Biology Society of Japan | 2017
Izumi Saito; Michiyo Nagano-Ito; Shinichi Ichikawa
The Japanese Biochemical Society/The Molecular Biology Society of Japan | 2017
Tomohiro Takahashi; Hiroaki Sekine; Shinichi Ichikawa
Collaboration
Dive into the Shinichi Ichikawa's collaboration.
Niigata University of Pharmacy and Applied Life Sciences
View shared research outputsNiigata University of Pharmacy and Applied Life Sciences
View shared research outputs